Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Puma Biotechnology, Inc.

Integrating the Evidence for Risk-Based Individualization of Adjuvant Therapy for HER2-Positive Breast Cancer

Release Date: March 31, 2021
Expiration Date: March 31, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in breast cancer. In this educational program, these experts discuss patient assessment for determining HER2 status as well as recently presented data sets on the management of early-stage HER2+ breast cancer. Faculty then apply this knowledge to clinical scenarios with case-based panel discussions.

This educational activity is an archive of the live virtual symposium held on March 5, 2021.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Puma Biotechnology, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, surgeons, pathologists, and fellows attending the 38th Annual Miami Breast Cancer Conference®. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Review expert guidelines regarding HER2 testing and characterization of HER2 status, as well as criteria for risk assessment.
  • Discuss adjuvant treatment strategies to reduce recurrence risk among patients with high-risk HER2+ breast cancer.
  • Integrate evidence from landmark clinical trials in the adjuvant and neoadjuvant settings into individualized treatment plans for patients with early-stage HER2+ breast cancer; and
  • Implement strategies for mitigating and managing adverse events associated with HER2-targeted therapies in order to minimize them and maintain treatment efficacy.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Debu Tripathy, MD
Debu Tripathy, MD
Professor and Chair, Department of Breast Medical Oncology, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Novartis, Polyphor; Consultant: Novartis, Pfizer Inc, AstraZeneca, GlaxoSmithKline, Genomic Health, OncoPep Inc.

Adam Brufsky, MD, PhD
Adam Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Director, Comprehensive Breast Cancer Center
UPMC Hillman Cancer Center
UPMC Magee-Women’s Hospital
University of Pittsburgh
Pittsburgh, PA

Disclosures: Consultant: BioArray Solutions Ltd, Novartis, Roche, Eisai Co, Celgene, Lilly, Pfizer Inc, Agendia, Genomic Health, NanoString Technologies, Biotheranostics Inc.

Mark Pegram, MD
Mark Pegram, MD
Director, Breast Cancer Oncology Program
Stanford Cancer Institute
Stanford, CA

Disclosures: Consultant: Genentech/Roche, Puma Biotechnology, Seagen Inc, Daiichi Sankyo.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By